US · CABA · BIOTECHNOLOGY
Cabaletta Bio, Inc. (CABA) intrinsic value and stock valuation
$0.94as of 2026-11-21 · Mkt cap 454.92M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cabaletta Bio, Inc. DCF and intrinsic value
InvestorsCraft values CABA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CABA’s statements →
Cabaletta Bio, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Allogene Therapeutics, Inc. (ALLO) $0.63
- Kyverna Therapeutics, Inc. (KYTX) $4.26
- Atea Pharmaceuticals, Inc. (AVIR) $3.96
- Lexeo Therapeutics, Inc. Common Stock (LXEO) $2.96
- Lyell Immunopharma, Inc. (LYEL) $13.80
- Editas Medicine, Inc. (EDIT) $1.64
- Capricor Therapeutics, Inc. (CAPR) $7.59
- ProQR Therapeutics N.V. (PRQR) $1.04
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-172.24M | -$-125.14M | -$-74.66M | -$-54.14M | -$-46.31M |
| Net income | -$-167.86M | -$-115.86M | -$-67.67M | -$-52.98M | -$-46.29M |
| EPSd | -$-1.64M | -$-2.34M | -$-1.65M | -$-1.81M | -$-1.8M |
| Operating cash flow | -$-131.08M | -$-88.22M | -$-53.55M | -$-46.38M | -$-34.11M |
| Capital expenditure | -$-1.23M | -$-2.21M | -$-690K | -$-2.45M | -$-1.17M |
| Free cash flow | -$-132.31M | -$-90.43M | -$-54.24M | -$-48.83M | -$-35.27M |
| Total assets | $165.1M | $185.1M | $253.7M | $117M | $126.3M |
| Total debt | $27.1M | $15.6M | $5.02M | $5.14M | $0.00 |
| Net debt | -$-55.88M | -$-148.36M | -$-188.22M | -$-76.47M | -$-122.22M |
| Total equity | $112.1M | $152.3M | $236.2M | $104.5M | $118M |
| Cash and short-term investments | $133.6M | $164M | $241.3M | $106.6M | $122.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $142.7M | $97.2M | $55.4M | $39.3M | $32.5M |
| Selling, general and administrative expenses | $29.6M | $27.9M | $19.2M | $14.8M | $13.8M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $172.2M | $125.1M | $74.7M | $54.1M | $46.3M |
| Cost and expenses | $172.2M | $125.1M | $74.7M | $54.1M | $46.3M |
| Interest income | $6.03M | $10M | $6.99M | $1.16M | $20K |
| Interest expense | $2M | $750K | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.65M | $1.71M | $1.43M | $1.18M | $730K |
| Ebitda | -$-164.21M | -$-113.41M | -$-66.25M | -$-51.8M | -$-45.56M |
| Operating income | -$-172.24M | -$-125.14M | -$-74.66M | -$-54.14M | -$-46.31M |
| Total other income/expenses, net | $4.38M | $9.28M | $6.99M | $1.16M | $20K |
| Income before tax | -$-167.86M | -$-115.86M | -$-67.67M | -$-52.98M | -$-46.29M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-167.86M | -$-115.86M | -$-67.67M | -$-52.98M | -$-46.29M |
| Weighted average shares outstanding | $102.3M | $49.5M | $41M | $29.3M | $25.7M |
| Weighted average diluted shares outstanding | $102.3M | $49.5M | $41M | $29.3M | $25.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $133.6M | $164M | $241.3M | $106.6M | $122.2M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $138.9M | $166.7M | $244.5M | $108.8M | $124.5M |
| Property, plant and equipment, net | $21.1M | $16.1M | $7.45M | $7.57M | $1.44M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $26.2M | $22.3M | $9.16M | $8.13M | $1.79M |
| Total assets | $165.1M | $185.1M | $253.7M | $117M | $126.3M |
| Accounts payable | $6.64M | $4.92M | $4.55M | $2.46M | $2.33M |
| Short-term debt | $24.2M | $9.97M | $3.56M | $2.18M | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $50.2M | $27.1M | $16M | $9.49M | $8.38M |
| Long-term debt | $2.88M | $5.62M | $1.46M | $2.96M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.88M | $5.62M | $1.46M | $2.96M | $0.00 |
| Capital lease obligations | $24.2M | $15.6M | $5.02M | $5.14M | $0.00 |
| Total liabilities | $53M | $32.7M | $17.5M | $12.5M | $8.38M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-516.96M | -$-349.1M | -$-233.24M | -$-165.56M | -$-112.59M |
| Accumulated other comprehensive income (loss) | $30K | $0.00 | $40K | -$-50K | $0.00 |
| Total equity | $112.1M | $152.3M | $236.2M | $104.5M | $118M |
| Total investments | $50.6M | $0.00 | $48M | $24.9M | $0.00 |
| Total debt | $27.1M | $15.6M | $5.02M | $5.14M | $0.00 |
| Net debt | -$-55.88M | -$-148.36M | -$-188.22M | -$-76.47M | -$-122.22M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-167.86M | -$-115.86M | -$-67.67M | -$-52.98M | -$-46.29M |
| Depreciation and amortization | $1.65M | $1.71M | $1.43M | $1.18M | $730K |
| Stock-based compensation | $20.9M | $19.5M | $11.3M | $6.9M | $5.8M |
| Change in working capital | -$-380K | $1.61M | $100K | -$-4.3M | $5.58M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $1.55M | $1.01M | $1.68M | -$-30K | $970K |
| Net cash provided by operating activities | -$-131.08M | -$-88.22M | -$-53.55M | -$-46.38M | -$-34.11M |
| Investments in property, plant and equipment | -$-1.23M | -$-2.21M | -$-690K | -$-2.45M | -$-1.17M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $20K | $0.00 |
| Net cash used for investing activities | -$-50.27M | $47.3M | -$-22.45M | -$-27.22M | $6M |
| Common stock issued | $106.6M | $10.9M | $185.2M | $32.9M | $48.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $100.4M | $11.7M | $187.6M | $33M | $48.9M |
| Net change in cash | -$-80.98M | -$-29.28M | $111.6M | -$-40.62M | $20.8M |
| Cash at end of period | $83M | $164M | $193.2M | $81.6M | $122.2M |
| Operating cash flow | -$-131.08M | -$-88.22M | -$-53.55M | -$-46.38M | -$-34.11M |
| Capital expenditure | -$-1.23M | -$-2.21M | -$-690K | -$-2.45M | -$-1.17M |
| Free cash flow | -$-132.31M | -$-90.43M | -$-54.24M | -$-48.83M | -$-35.27M |
Line items
Line items
Line items
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
- CEO
- Steven A. Nichtberger
- Employees
- 156
- Beta
- 3.26
Explore
Frequently asked questions
What is the intrinsic value of Cabaletta Bio, Inc. (CABA)?
InvestorsCraft does not currently publish an intrinsic value for CABA. How the IC value is calculated.
Is CABA undervalued?
InvestorsCraft does not publish an undervaluation signal for CABA at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.